Nucleai

🎓 Nucleai Academy returns this September! Resistance to immunotherapy remains one of the biggest challenges in oncology. Join us as Dr. Ettai Markovits presents emerging evidence of a novel predictive biomarker signature, identified through a collaborative study with the University of Queensland and Yale University. Using multiplex immunofluorescence (mIF) combined with Nucleai’s deep learning platform, the study revealed a metabolic signature associated with treatment resistance in NSCLC and HNSCC patient samples and offers a scalable framework for extracting clinically relevant biomarker signatures from complex mIF datasets. 📅 Register now: https://xmrrwallet.com/cmx.pbit.ly/46QfoIz #NucleaiAcademy #ImmunotherapyResistance #SpatialBiomarkers #DigitalPathology #ImmunoOncology #mIF #BiomarkerDiscovery #PrecisionMedicine

𝗤𝘂𝗮𝗹𝗶𝗳𝘆 𝗔𝗗𝗖 𝗮𝗻𝗱 𝗠𝘂𝗹𝘁𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗧𝗮𝗿𝗴𝗲𝘁𝘀 𝘄𝗶𝘁𝗵 𝗔𝗜-𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗦𝗽𝗮𝘁𝗶𝗮𝗹 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 While genomic alterations have become important biomarkers for predicting response to targeted therapies, next-generation treatments like ADCs and multispecifics demand a different class of biomarkers that can quantify and localize drug targets within tumor and immune cells, including their subcellular expression patterns. Nucleai’s platform enables deep spatial proteomic profiling by deriving AI-driven insights for actionable characterization of protein interactions and patient heterogeneity across tissues. In our latest AACR 2025 poster, we demonstrate that this framework can aid in the prioritization and de-risking of potential drug targets used by key classes of therapeutics currently in development. 📥 Download the full poster. https://xmrrwallet.com/cmx.pbit.ly/3GRt3Ez #biomarkers #spatialbiomarkers #digitalpathology #aipathology #precisionmedicine #ADC

𝐃𝐞𝐫𝐢𝐬𝐤 𝐀𝐃𝐂 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐀𝐈-𝐩𝐨𝐰𝐞𝐫𝐞𝐝 𝐐𝐂𝐒 𝐚𝐧𝐝 𝐬𝐩𝐚𝐭𝐢𝐚𝐥 𝐩𝐫𝐨𝐱𝐢𝐦𝐢𝐭𝐲 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬. Antibody-drug conjugates hold great promise in oncology, but tumor heterogeneity, complex mechanisms of action, and resistance make development challenging. Nucleai’s AI-powered spatial inference platform supports ADC development with: ✅ OD-based scoring for more sensitive and quantitative analysis of IHC assays ✅ Spatial mapping of target distribution and tumor heterogeneity ✅ Bystander effect modeling through tunable spatial proximity analysis ✅ Off-target toxicity and immunogenicity risk assessment ✅ Biomarker-informed trial design. 📩 Contact us to book a demo https://xmrrwallet.com/cmx.pbit.ly/4lFVLar #SpatialBiomarkers #AIpathology #DigitalPathology #Biomarkers #ADC #ClinicalTrials #AntibodyDrugConjugates #PrecisionMedicine

Our Head of Pathology, Dr. Ken Bloom, had the pleasure of joining a recent Drug Discovery World panel hosted by Proscia alongside leading industry experts, to discuss how digital pathology and AI are accelerating biopharma R&D and enabling more precise, data-driven decisions. Ken spoke about the role of AI-powered spatial proteomics in de-risking the development of next-generation therapies such as multispecifics, immunotherapies, and ADCs by transforming complex tissue data into clinically meaningful insights. He shared real-world examples from Nucleai’s work, including: ✔️AI-powered spatial scoring to understand the complex MOA of multispecific drugs ✔️Discovery of novel spatial signatures linked to resistance in IO therapy ✔️QCS and spatial proximity analysis to support effective patient selection for ADCs Thank you to fellow panelists Nathan Buchbinder (Proscia), Vipul Baxi, MS, MBA (Amgen), and Deirdre De Steno PhD MBA (OWKIN) for a dynamic and insightful discussion. 🎥 Watch the full session on demand: https://xmrrwallet.com/cmx.pbit.ly/3TH0QTN #Immunotherapy #Biomarkers #PrecisionMedicine #SpatialBiomarkers #ImmunoOncology #DigitalPathology #AIpathology #Multispecifics #AntibodyDrugConjugates

In honor of Cancer Immunotherapy Month, we're highlighting recent research that explores how AI-powered spatial biomarkers can help uncover insights into the tumor microenvironment and support a better understanding of treatment response and resistance. From head & neck cancer to melanoma and NSCLC, our studies presented at #ASCO25, #AACR25, #SITC24 and #ESMO24 showcase the potential of spatial analysis to inform immunotherapy strategies.   Swipe through to explore our immuno-oncology studies https://xmrrwallet.com/cmx.plnkd.in/grXfdtCA #Immunotherapy #biomarkers #digitalpathology #aipathology #Immune2Cancer #spatialbiomarkers #ImmunoOncology #precisionmedicine 

❗Missed our latest Nucleai Academy on OD-based Scoring for ADCs? The full session with Dr. Ken Bloom is now available on demand. Learn how OD-based biomarker scoring and spatial analysis can help address key challenges in ADC development—such as target distribution and heterogeneity, patient stratification, and complex mechanisms-of-action. 📺 Watch the recording: https://xmrrwallet.com/cmx.plnkd.in/gTMvtdVV #nucleaiacademy #biomarkers #precisionmedicine #spatialbiomarkers #aipathology #digitalpathology

📢This coming Monday, join Dr. Ken Bloom as he explores the challenges of patient selection for ADCs—and how OD-based biomarker scoring and computational pathology can provide deeper insights into target expression and drug activity. 📅 Monday, June 16 | 11:00 AM ET 🔗 RSVP ➡️ https://xmrrwallet.com/cmx.phubs.li/Q03rZc330 #NucleaiAcademy #ADC #BiomarkerScoring #ComputationalPathology #SpatialBiomarker #DigitalPathology #PrecisionMedicine

One week to go! 🎓 Join Dr. Ken Bloom on June 16 for a live Nucleai Academy webinar exploring how OD-based quantitative biomarker scoring and spatial analysis can support ADC drug development. Topics include: ✔️ OD-based scoring of IHC assays for subcellular protein expression ✔️ AI-powered spatial proximity scoring for modeling bystander effects ✔️ mIF for target identification, bispecific credentialing, and MOA studies 📅 Monday, June 16 | 11:00 AM ET RSVP ➡️ https://xmrrwallet.com/cmx.plnkd.in/ggHvz2AN #SpatialBiomarker #NucleaiAcademy #ADC #AIpathology #DigitalPathology #PrecisionMedicine #Biomarker #BiomarkerScoring

Closing out an incredible week at #ASCO25! Thank you to everyone who stopped by, shared insights, or joined the conversation. Couldn’t make it to Chicago? We’re offering virtual live demos of our ADC solution suite → https://xmrrwallet.com/cmx.pbit.ly/4kqAfpJ #SpatialBiomarkers #DigitalPathology #PrecisionOncology #AIPathology

Our #ASCO2025 poster on predictive spatial biomarkers in immunotherapy-treated melanoma is now live on our website. In this study, we present new data, in collaboration with Lunaphore (a Bio-Techne brand) and Dr. Paolo A. Ascierto (National Cancer Institute, Naples), using mIF and AI-powered spatial analysis to uncover tumor microenvironment features linked to treatment response in immunotherapy-treated melanoma. 📄 View the full poster → https://xmrrwallet.com/cmx.pbit.ly/4mI1dKZ #ASCO25 #SpatialBiomarkers #Immunotherapy #mIF #Melanoma